US FDA Commissioner Scott Gottlieb believes the potential for "review efficiencies" will entice manufacturers to allow public posting of their clinical study reports (CSRs) after a drug application's approval.
Whether this is enough of a carrot stick to persuade manufacturers to allow the release of their clinical trial data...








